Ofev is the brand name for nintedanib, a tyrosine kinase inhibitor manufactured and marketed by Boehringer Ingelheim. The FDA first approved Ofev on October 15, 2014, for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal scarring disease of the lung tissue. Subsequent FDA approvals expanded the label: Ofev is now also indicated for chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype and for systemic sclerosis-associated interstitial lung disease (SSc-ILD). Ofev works by blocking multiple signaling pathways involved in fibrotic growth, distinguishing it mechanistically from pirfenidone (Esbriet), the other FDA-approved antifibrotic for IPF.
Ofev's 2026 list price of approximately $12,600 per month makes it one of the costliest oral specialty drugs in the United States. Because Ofev is a specialty medication, most insurance plans including Medicare Part D route the prescription through a contracted specialty pharmacy rather than a retail counter, which means standard retail discount programs like the Walmart $4 generic list do not apply. Patients with commercial insurance who face a high specialty-tier formulary copay can apply for the Ofev Commercial Copay Program (run by Boehringer Ingelheim), which can reduce monthly cost-sharing to as little as $0 per month. Patients without insurance or with Medicare who meet income guidelines should apply for the Boehringer Cares Patient Assistance Program, which provides Ofev free to those at or below 400 percent of the federal poverty level.
Ofev was selected by CMS for the second round of Medicare drug price negotiation under the Inflation Reduction Act of 2022. CMS announced a negotiated Maximum Fair Price of $6,350 per month, down from Ofev's list price of $12,622 at the time of negotiation, representing a 49.7 percent reduction. Medicare beneficiaries will pay the lower Maximum Fair Price starting January 1, 2027. In 2026, Medicare patients still pay based on the unreduced list price under their plan's cost-sharing structure, though the $2,100 annual Part D out-of-pocket cap provides meaningful protection. Patients who rely on Medicare coverage for Ofev should plan for 2027 as the year their cost-sharing drops substantially, and review their plan during the 2026 Annual Enrollment Period (October 15 to December 7) to ensure Ofev is on formulary at the most favorable tier.
What Ofev Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same ofev can cost many times more at a hospital than at your local pharmacy:
2026 Ofev Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash) | $12,000 - $13,500/month | 2026 list price without insurance for 60 capsules (150 mg twice daily). Dispensed only through specialty pharmacies. |
| Medicare Part D (2026) | $0 - $2,100/year total OOP, capped at $2,100 annual | Specialty Tier 5 drug; prior authorization required. Total Part D OOP capped at $2,100 per year (2026). Starting January 1, 2027, the IRA Maximum Fair Price drops the base cost to $6,350/month. |
| Commercial insurance (specialty tier) | $0 - $500/month with copay card | Prior authorization and sometimes step therapy required. The Ofev Commercial Copay Program can reduce cost-sharing to as little as $0/month for eligible commercially insured patients. |
| Boehringer Cares PAP (uninsured or Medicare, income-based) | $0 (free) for income at or below 400% FPL | Available to uninsured and Medicare patients; not available to those with commercial insurance. Income must be at or below 400% of the federal poverty level. |
| Medicaid | $1 - $4/prescription | Covered where medically necessary; prior authorization required; copay varies by state (typically $1-$4 nominal). |
Retail prices reflect 2026 specialty pharmacy and GoodRx survey data. Part D ranges depend on your plan's formulary tier placement, deductible phase, and where you are in your benefit year. The IRA-negotiated Maximum Fair Price of $6,350/month takes effect January 1, 2027.
Source: CMS Part D 2026 benefit design, CMS IRA Round 2 negotiated prices (IPAY 2027), Boehringer Ingelheim savings programs, GoodRx
Why Hospitals Charge So Much
Ofev is almost never administered in an inpatient hospital setting because it is an oral specialty drug taken at home twice daily. When Ofev does appear on an inpatient bill, it is typically because a patient was admitted while already on the medication and the hospital's in-house specialty pharmacy dispensed a short supply. Hospital specialty pharmacies charge acquisition cost plus layers of facility fees: a dispensing fee, nursing administration documentation fees, overhead recovery charges, and in some facilities a specialty drug handling surcharge. A month's supply that retails at around $12,600 through a specialty pharmacy can appear on an inpatient itemized bill at $18,000 to $28,000 or more.
Patients who see Ofev on an inpatient or facility-based bill well above the known specialty pharmacy list price should request an itemized statement and look for the NDC code beginning with 00597. Wholesale acquisition cost for 60 nintedanib 150 mg capsules in 2026 is approximately $12,600. A hospital charge significantly above that is likely a facility markup. Commercial insurers and Medicare Part D plans typically pay at a drug-cost rate tied to the negotiated specialty pharmacy price, not the facility's inflated charge, which can leave the difference as a patient balance. Disputing the charge in writing and asking for the facility's 340B or WAC-based rate often results in a substantial reduction.
Three structural factors explain why specialty drugs like Ofev cost far more at a hospital than through an outpatient specialty pharmacy. First, hospitals can mark up drug acquisition costs without the same price transparency requirements that apply to retail pharmacies. Second, inpatient pharmacy billing is often bundled under facility-fee codes that are opaque to insurers and patients alike. Third, most IPF patients receive Ofev through a specialty pharmacy network contracted by their insurer, which typically carries a negotiated rate lower than hospital acquisition cost. If you receive a hospital bill that includes Ofev charges, compare that charge to the specialty pharmacy list price and use the CoveredUSA Medical Bill Analyzer to identify disputable line items.
Patient Assistance Programs
Boehringer Ingelheim, the manufacturer of Ofev, operates two programs that can dramatically lower or eliminate out-of-pocket cost depending on your insurance status. Patients with commercial insurance who face high specialty-tier copays use the Ofev Commercial Copay Program. Patients who are uninsured or covered by Medicare or Medicaid but cannot afford Ofev's list price can apply for the Boehringer Cares Patient Assistance Program, which provides Ofev free when household income is at or below 400 percent of the federal poverty level.
Patient assistance programs for Ofev| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Ofev Commercial Copay Program | As little as $0/month for commercially insured patients; maximum monthly savings apply; up to 16 fills per year | 855-396-2603 or specialty pharmacy enrollment |
| Boehringer Cares Patient Assistance Program | Free Ofev for uninsured or Medicare patients at or below 400% FPL; commercial insurance typically disqualifies | boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/boehringer-cares-patient-assistance-portal |
| NeedyMeds Drug Discount Card | Variable discount accepted at participating pharmacies; primarily useful for non-specialty situations | needymeds.org |
Manufacturer savings cards and copay assistance programs (including the Ofev Commercial Copay Program) are not available to beneficiaries of Medicare, Medicaid, TRICARE, or VA benefits under federal anti-kickback statute (42 U.S.C. § 1320a-7b). If you have any form of government health coverage, you must use the income-based Boehringer Cares Patient Assistance Program rather than the commercial copay card.
Source: Boehringer Ingelheim Ofev savings programs, boehringer-ingelheim.com/us, NeedyMeds.org
Medicare Part D
Ofev is a Medicare Part D drug, meaning it is covered under Medicare's outpatient prescription drug benefit rather than under Part B. In 2026, virtually all Part D plans that include Ofev on formulary place it in the specialty tier (Tier 5), which typically requires the highest cost-sharing percentage before deductible and initial coverage phases are exhausted. The 2026 Part D benefit design provides important protection: your total out-of-pocket spending across all covered Part D drugs is capped at $2,100 for the year. For a drug priced above $12,000 per month, most Medicare beneficiaries taking Ofev will reach that $2,100 annual cap early in the calendar year.
Medicare Part D prior authorization for Ofev requires documentation of an IPF, progressive fibrosing ILD, or SSc-ILD diagnosis, typically including pulmonary function tests, a CT scan of the chest, and a prescriber attestation that the patient has been evaluated by a pulmonologist. Denial rates for initial PA requests for Ofev are notable, often due to missing imaging or incomplete diagnostic documentation. If your plan denies Ofev, ask your pulmonologist to submit a peer-to-peer review within 48 to 72 hours of the denial. For Medicare beneficiaries, the Medicare Part D appeals process allows you to file an expedited appeal if your prescriber certifies that the standard timeframe would seriously jeopardize your health. Check the CMS Medicare drug plan finder at medicare.gov to compare 2026 Part D plans that include Ofev at the most favorable tier.
Starting January 1, 2027, Medicare beneficiaries will benefit from the IRA-negotiated Maximum Fair Price of $6,350 per month for Ofev. That negotiated price, announced by CMS as part of the second round of Medicare drug price negotiation, represents a 49.7 percent reduction from Ofev's 2024-era list price of $12,622. In practice, the lower Maximum Fair Price means that Medicare's cost-sharing calculations for Ofev will be based on $6,350 rather than $12,622, reducing what patients owe in their deductible and initial coverage phases before reaching the $2,100 annual cap. Patients who currently spend months reaching the cap will likely reach it faster after January 2027, and many will cross the $2,100 threshold within the first two to three months of the year.
Common Ofev Billing Errors
If you received a bill for Ofev that is higher than expected, check for these common errors before paying:
- Prior authorization not obtained or allowed to lapse: Ofev PA approvals are typically valid for 12 months. If your prescriber's office did not renew the PA before it expired, your plan may deny the claim and bill you the full cash price.
- Dispensed by an out-of-network specialty pharmacy: if your prescription was filled at a specialty pharmacy not in your plan's network, you may be billed at a non-preferred or cash rate. Always confirm network status with your plan before first fill.
- Charged the $2,100 Part D deductible phase after you have already met your deductible, or billed at the full coinsurance rate after you have reached the $2,100 annual out-of-pocket cap.
- Inpatient hospital charges for Ofev at facility rates far above specialty pharmacy WAC. Request an itemized bill and compare to the specialty pharmacy list price of approximately $12,600 per month in 2026.
- Savings card or manufacturer coupon not applied: if you are commercially insured and enrolled in the Ofev Commercial Copay Program, confirm with your specialty pharmacy that the program was applied to your most recent fill. The BIN/PCN is different from a standard GoodRx coupon.
Frequently Asked Questions
Is there a generic for Ofev (nintedanib) in 2026?
No commercially available generic nintedanib exists in the United States in 2026. The FDA approved generic nintedanib capsules from Cipla and Apotex in 2025 and 2026, but Boehringer Ingelheim holds formulation and method-of-use patents on Ofev that are not expected to expire until approximately 2029. FDA approval of a generic does not mean the generic can be sold; patent exclusivity legally blocks commercial launch until those patents expire or are successfully challenged. Patients needing a less expensive antifibrotic alternative should ask their pulmonologist about generic pirfenidone, which is a separate compound (approved generic of Esbriet) and available at a substantially lower cost.
How do I apply for the Boehringer Cares Patient Assistance Program for Ofev?
Call 1-800-556-8317 or visit boehringer-ingelheim.com/us to start the Boehringer Cares Patient Assistance Program application. You will need: your most recent federal tax return or four pay stubs (income at or below 400 percent of the 2026 federal poverty level is required); proof of US residency; a valid Ofev prescription from a pulmonologist; and your prescriber's completed attestation section. Medicare patients must also show they applied for Medicare Extra Help (Low Income Subsidy). Submit completed forms by fax to 1-866-851-2827 or mail to the Jeffersontown, KY address. Processing takes 7 to 14 business days. The program is not available to commercially insured patients.
Can I use the Ofev Commercial Copay Program with Medicare?
No. Federal anti-kickback statute (42 U.S.C. § 1320a-7b) bars manufacturer copay assistance cards from being used by beneficiaries of Medicare, Medicaid, TRICARE, or VA coverage. The Ofev Commercial Copay Program is exclusively for patients with private commercial insurance. If you have Medicare, your options are the Boehringer Cares Patient Assistance Program (free Ofev if income is at or below 400 percent of the 2026 federal poverty level) or the Medicare Part D $2,100 annual out-of-pocket cap, which provides significant cost protection for a drug in this price range.
Does the IRA Medicare negotiation apply to Ofev?
Ofev was selected for Medicare price negotiation under the Inflation Reduction Act of 2022 as part of the second round of negotiations (Initial Price Applicability Year 2027). CMS announced a Maximum Fair Price of $6,350 per month for Ofev, down from a list price of $12,622, representing a 49.7 percent reduction. This negotiated price takes effect January 1, 2027, and applies to Medicare Part D enrollees. In 2026, Medicare beneficiaries still pay based on Ofev's current list price structure under their plan's benefit design, with out-of-pocket costs capped at the 2026 annual Part D limit of $2,100.
What if my insurance denies coverage for Ofev?
Request the written denial immediately and file a formal first-level appeal within 60 days. Attach clinical documentation including your pulmonary function test results, chest CT report, and pulmonologist's notes confirming the IPF or progressive fibrosing ILD diagnosis. Ask your prescriber to request a peer-to-peer review with the plan's medical director, as physician-to-physician calls frequently reverse specialty drug denials. If your plan requires pirfenidone first (step therapy), your prescriber can file a step-therapy exception. If internal appeals fail, escalate to an independent external review. During any appeal, apply to the Boehringer Cares Patient Assistance Program as a bridge so you do not miss doses.
What does Ofev cost without insurance at the pharmacy counter in 2026?
Ofev's 2026 list price is approximately $12,000 to $13,500 per month for the standard 150 mg twice-daily regimen (60 capsules). Ofev is a specialty-restricted drug that must be dispensed through specialty pharmacies such as CVS Specialty or AllianceRx Walgreens Pharmacy; standard retail counter pricing does not apply. GoodRx coupons can reduce the cost to approximately $2,178 for 60 capsules at participating specialty pharmacies, but insurance or the manufacturer assistance program nearly always produces a lower cost for eligible patients. Uninsured patients at or below 400 percent of the 2026 federal poverty level should apply for the Boehringer Cares Patient Assistance Program for free Ofev.
Do I qualify for the Boehringer Cares patient assistance program?
To qualify for the Boehringer Cares Patient Assistance Program for Ofev, you must: (1) be a US resident or citizen; (2) have a valid Ofev prescription for IPF, progressive fibrosing ILD, or SSc-ILD; (3) have annual household income at or below 400 percent of the 2026 federal poverty level (that is $63,840 for a household of 1, $86,560 for a household of 2, and $132,000 for a household of 4); (4) be uninsured, have Medicare, or have Medicaid (commercial insurance typically disqualifies you). Medicare patients must also show they applied for the Medicare Low Income Subsidy. The income thresholds are based on the 2026 HHS poverty guidelines.
How does Ofev compare to pirfenidone (Esbriet) in cost?
Ofev (nintedanib) and pirfenidone (Esbriet) are both FDA-approved antifibrotics for idiopathic pulmonary fibrosis with broadly similar list prices in the range of $12,000 to $13,000 per month in 2026. Esbriet is no longer sold under that brand name by Genentech/Roche after the brand was discontinued in the US; however, generic pirfenidone capsules were FDA-approved in 2022 and are available at significantly lower prices (roughly $800 to $2,000 per month depending on the pharmacy and generic tier). If your prescriber determines pirfenidone is clinically appropriate for your specific ILD subtype, the generic pirfenidone option may substantially lower your monthly cost. Ofev has a distinct indication advantage for SSc-ILD and some progressive fibrosing ILD subtypes where pirfenidone is not labeled.
